loading
Schlusskurs vom Vortag:
$3.31
Offen:
$3.33
24-Stunden-Volumen:
82,018
Relative Volume:
0.24
Marktkapitalisierung:
$178.70M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
5.5082
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
+5.16%
1M Leistung:
-2.33%
6M Leistung:
+9.09%
1J Leistung:
+4.02%
1-Tages-Spanne:
Value
$3.26
$3.355
1-Wochen-Bereich:
Value
$3.185
$3.39
52-Wochen-Spanne:
Value
$2.225
$4.13

Puma Biotechnology Inc Stock (PBYI) Company Profile

Name
Firmenname
Puma Biotechnology Inc
Name
Telefon
(424) 248-6500
Name
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Name
Mitarbeiter
172
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PBYI's Discussions on Twitter

Vergleichen Sie PBYI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PBYI
Puma Biotechnology Inc
3.355 178.70M 230.47M 30.28M 38.86M 0.61
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.12 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
528.17 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.62 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.84 28.51B 3.81B -644.79M -669.77M -6.24

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-09-28 Hochstufung Citigroup Neutral → Buy
2020-06-25 Fortgesetzt BofA/Merrill Underperform
2019-10-08 Herabstufung Goldman Neutral → Sell
2019-05-10 Herabstufung Cantor Fitzgerald Overweight → Neutral
2019-05-10 Herabstufung Citigroup Buy → Neutral
2019-01-17 Eingeleitet Leerink Partners Mkt Perform
2019-01-03 Herabstufung Guggenheim Buy → Neutral
2018-11-19 Hochstufung Goldman Sell → Neutral
2018-11-02 Herabstufung BofA/Merrill Buy → Underperform
2018-11-02 Herabstufung JP Morgan Neutral → Underweight
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-09-17 Eingeleitet Goldman Sell
2018-05-11 Bestätigt Stifel Buy
2017-11-10 Bestätigt Citigroup Buy
2017-11-10 Bestätigt RBC Capital Mkts Sector Perform
2017-10-02 Bestätigt Stifel Buy
2017-09-11 Bestätigt Credit Suisse Outperform
2017-07-10 Fortgesetzt Leerink Partners Outperform
2017-06-06 Bestätigt RBC Capital Mkts Sector Perform
2017-05-25 Bestätigt RBC Capital Mkts Sector Perform
2017-03-02 Bestätigt RBC Capital Mkts Sector Perform
Alle ansehen

Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten

pulisher
Jun 13, 2025

Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance

Jun 10, 2025
pulisher
Jun 08, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan

Jun 04, 2025
pulisher
May 28, 2025

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise

May 28, 2025
pulisher
May 26, 2025

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance

May 26, 2025
pulisher
May 20, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st

May 20, 2025
pulisher
May 17, 2025

Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

May 17, 2025
pulisher
May 17, 2025

Puma Biotechnology Inc (PBYI) Forecast: Revisiting The Past To Gain Insights For The Future - Stocksregister

May 17, 2025
pulisher
May 15, 2025

Puma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable Quality - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN

May 14, 2025
pulisher
May 14, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by Wells Fargo & Company MN - Defense World

May 14, 2025
pulisher
May 12, 2025

Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock - Nasdaq

May 12, 2025
pulisher
May 12, 2025

PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - MSN

May 12, 2025
pulisher
May 10, 2025

Puma Biotechnology First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Puma Biotech CCO Jeff Ludwig departs, no replacement named By Investing.com - Investing.com Canada

May 10, 2025
pulisher
May 10, 2025

Puma Biotech CCO Jeff Ludwig departs, no replacement named - Investing.com

May 10, 2025
pulisher
May 09, 2025

Puma Biotechnology, Inc. Announces Termination of Jeff J. Ludwig as Chief Commercial Officer - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Puma Biotechnology Terminates Chief Commercial Officer - TipRanks

May 09, 2025
pulisher
May 09, 2025

Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Puma Biotechnology Reports Positive Q1 2025 Earnings - TipRanks

May 09, 2025
pulisher
May 08, 2025

Puma Biotech Q1 2025 slides: NERLYNX revenue up 7% YoY despite quarterly decline - Investing.com Canada

May 08, 2025
pulisher
May 08, 2025

Puma Biotech: Q1 Earnings Snapshot - The Washington Post

May 08, 2025
pulisher
May 08, 2025

Cautious Hold Rating on Puma Biotechnology Amid Declining Sales and Uncertain Trial Outcomes - TipRanks

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts By Investing.com - Investing.com UK

May 08, 2025
pulisher
May 08, 2025

Puma Biotechnology Reports First Quarter Financial Results - BioSpace

May 08, 2025
pulisher
May 08, 2025

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts - Investing.com

May 08, 2025
pulisher
May 01, 2025

Check out these key findings about Puma Biotechnology Inc (PBYI) - Sete News

May 01, 2025
pulisher
Apr 30, 2025

Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients - The Manila Times

Apr 30, 2025
pulisher
Apr 30, 2025

Er-Kim Announces Exclusive Distribution Agreement with Puma - GlobeNewswire

Apr 30, 2025
pulisher
Apr 28, 2025

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo Finance

Apr 28, 2025

Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Stuglik Brian M
Director
Jun 13 '25
Sale
3.39
8,100
27,459
94,958
Senderowicz Adrian
Director
Jun 13 '25
Sale
3.40
27,000
91,800
27,000
MOYES JAY M
Director
Jun 13 '25
Sale
3.40
22,000
74,800
53,322
Dorval Allison
Director
Jun 13 '25
Sale
3.40
11,610
39,474
75,390
Cesano Alessandra
Director
Jun 13 '25
Sale
3.40
12,150
41,310
68,850
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
Kapitalisierung:     |  Volumen (24h):